Medical Device Companies

Software as a Medical Device (SaMD) can move from development to clinical use faster than many traditional medical products, but that doesn't make the regulatory process simple. A software function that analyzes medical images, supports diagnosis, monitors a patient, or provides clinical recommendations can raise important questions about safety, performance, cybersecurity, and ongoing changes.

For companies bringing SaMD to the U.S. market, regulatory planning should start with the software's intended use and potential risks—not with the submission form.

What Should Companies Consider When Classifying SaMD?

The intended use is one of the most important starting points. Manufacturers need to clearly define what the software does, who uses it, what information it provides, and how that information may affect patient care.

The device's risk profile then helps inform the appropriate FDA pathway. Depending on the product, a company may pursue 510(k) clearance, De Novo classification, or Premarket Approval (PMA). The pathway determines the type and depth of evidence the FDA will expect.

Getting this decision right early matters. A poorly defined intended use can create problems across labeling, clinical evaluation, risk management, and submission documentation.

How Do Risk Assessment and Software Validation Fit Together?

Software risk assessment should consider reasonably foreseeable hazards, including incorrect outputs, software failures, data problems, interoperability issues, and situations where users misunderstand or misuse the product.

Verification and validation provide evidence that the software was developed correctly and performs as intended. Testing can cover requirements, architecture, individual software units, integrations, cybersecurity controls, and complete system behavior.

A strong approach connects requirements to testing rather than treating verification as a final-stage exercise. If a requirement matters for patient safety, there should be evidence demonstrating that the software meets it.

What About Clinical Evaluation and Human Factors?

Some SaMD products require clinical evidence to demonstrate that their outputs are clinically meaningful and appropriate for the intended use. The level of evidence depends on the device, its claims, risks, and regulatory pathway.

Human factors are equally important. Even technically accurate software can create risks if users misunderstand alerts, interpret results incorrectly, or struggle with the interface. Usability engineering should therefore consider realistic users, environments, workflows, and foreseeable use errors.

Why Are Cybersecurity and Quality Systems Important?

Connected medical software creates cybersecurity considerations that extend beyond traditional software development. Manufacturers should consider threats that could affect confidentiality, integrity, availability, and—most importantly—device safety and performance.

SaMD development also needs to operate within applicable quality-system and design-control requirements. Design inputs, outputs, reviews, verification, validation, risk management, software changes, and documentation should fit together as a coherent development process.

For AI- and machine-learning-enabled devices, this becomes even more important because software may evolve over time.

What Are FDA PCCP Requirements for AI-Enabled Devices?

FDA PCCP requirements are particularly relevant when manufacturers anticipate making predefined changes to an AI/ML-enabled medical device after authorization.

A Predetermined Change Control Plan (PCCP) can describe planned modifications and the methodology that will be used to implement and validate those changes without treating every anticipated modification as an entirely new regulatory submission. The details matter, though. The proposed changes and associated validation methods need to be appropriately defined and supported.

For manufacturers, the practical lesson is simple: don't treat future AI changes as an afterthought. Consider them during product development and regulatory strategy.

How Can E & E Medicals Help?

E & E Medicals & Consulting is an Atlanta-based medical device regulatory and quality consulting firm supporting medical device, IVD, and pharmaceutical companies with FDA submissions, global market authorization, and quality-system compliance.

With more than 32 years of combined experience, E & E Medicals provides strategic regulatory guidance, gap analysis, and hands-on implementation support. Whether a company is developing SaMD, preparing an FDA submission, strengthening design controls, or planning changes to an AI-enabled device, experienced regulatory input can help identify gaps before they become expensive problems.

The objective is practical: help companies navigate complex requirements and bring products to market safely and efficiently.

FAQs

What is SaMD?

Software as a Medical Device refers broadly to software intended to perform one or more medical purposes without being part of a hardware medical device. Its regulatory treatment depends on its intended use, functionality, and risk.

What are FDA PCCP requirements?

FDA PCCP requirements concern the documentation and controls for predetermined changes to certain medical devices, including applicable AI/ML-enabled devices. A PCCP should clearly describe the planned modifications and the methodology for developing, validating, and implementing them.

Does SaMD need clinical evidence?

It depends on the device, intended use, claims, risk, and FDA regulatory pathway. Some software products may require clinical evaluation or clinical data to support safety and effectiveness, while the evidence needed can vary considerably between devices.